Research and Markets presents a comprehensive analysis of AI-driven drug discovery, detailing how machine learning, deep learning, and NLP optimize target identification and repurposing, projecting the market’s rise from $1.72B to $8.53B by 2030 across global regions.
Key points
- Market valued at $1.72B in 2024 and projected to reach $8.53B by 2030 with a 30.59% CAGR
- Integration of machine learning, deep learning, and NLP accelerates target identification, protein prediction, and drug repurposing
- North America leads with 43% share, while Europe and APAC grow through supportive regulations and national AI strategies
Why it matters: AI-driven drug discovery offers unprecedented speed and cost efficiency, reshaping pharmaceutical R&D and accelerating therapeutic development.
Q&A
- How does AI improve drug target identification?
- What is the role of AlphaFold in drug discovery?
- Why is the North American market leading in AI drug discovery?
- What challenges hinder AI adoption in drug discovery?
